SCHEMBL3020518

SCHEMBL3020518

Cc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(Cl)c(Cl)c4)CC3)n2)cc1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LPAR2 Q9HBW0 6/20 0.45
LPAR1 Q92633 5/20 0.45
ALDH1A1 P00352 4/20 0.43
HTT P42858 2/20 0.43
KDM4E B2RXH2 2/20 0.43
ADRB3 P13945 1/20 0.43
TSPO P30536 1/20 0.43
DRD3 P35462 1/20 0.43
OPRK1 P41145 1/20 0.43
TMEM97 Q5BJF2 1/20 0.43
LPAR4 Q99677 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
GPR35 Q9HC97 1/20 0.43
LPAR3 Q9UBY5 1/20 0.43
PKM P14618 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3021973 0.92 THRB (0.47) THRBSMN1; SMN2MEN1KMT2ALPAR2
SCHEMBL3013719 0.92 LPAR1 (0.45) SMN1; SMN2MEN1KMT2ALPAR2LPAR1
SCHEMBL3017242 0.91 ALDH1A1 (0.46) THRBSMN1; SMN2ALDH1A1HTTKDM4E
SCHEMBL3017901 0.90 THRB (0.47) THRBSMN1; SMN2MEN1KMT2ALPAR2
SCHEMBL3015254 0.89 ALDH1A1 (0.42) SMN1; SMN2MEN1KMT2AALDH1A1HTT
SCHEMBL3651838 0.89 VCAM1 (0.50) THRBSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL3017192 0.89 ALDH1A1 (0.46) SMN1; SMN2MEN1KMT2AALDH1A1HTT
SCHEMBL3014192 0.89 LMNA (0.47) SMN1; SMN2MEN1KMT2ALPAR2ALDH1A1
SCHEMBL3014321 0.88 THRB (0.57) THRBSMN1; SMN2MEN1KMT2ALPAR2
SCHEMBL3007413 0.88 SMN1; SMN2 (0.46) THRBSMN1; SMN2MEN1KMT2ALPAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA THRB 2628/4885SMN1; SMN2 1/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.